SCHEMBL435033

SCHEMBL435033

CCC(C(=O)OC)C(c1ccccc1)c1ccc(OCc2ccc(OCC(=NOC)c3ccccc3)cc2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 3/20 0.57
LTA4H P09960 1/20 0.42
PPARG P37231 1/20 0.41
ALDH1A1 P00352 3/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
HTT P42858 2/20 0.41
MAPT P10636 2/20 0.41
RAB9A P51151 2/20 0.41
GAA P10253 1/20 0.41
L3MBTL1 Q9Y468 2/20 0.40
LMNA P02545 1/20 0.40
RXRA P19793 1/20 0.40
RXRB P28702 1/20 0.40
KDM4E B2RXH2 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
PLA2G4B P0C869 2/20 0.39
YAP1 P46937 1/20 0.39
PPARA Q07869 1/20 0.38
NPC1 O15118 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL435031 0.85 FFAR1 (0.57) FFAR1ALDH1A1SMN1; SMN2HTTMAPT
SCHEMBL435962 0.83 FFAR1 (0.60) FFAR1LTA4HPPARGALDH1A1SMN1; SMN2
SCHEMBL435961 0.83 FFAR1 (0.60) FFAR1LTA4HPPARGALDH1A1SMN1; SMN2
SCHEMBL433313 0.82 FFAR1 (0.66) FFAR1ALDH1A1SMN1; SMN2HTTL3MBTL1
SCHEMBL433312 0.82 FFAR1 (0.66) FFAR1ALDH1A1SMN1; SMN2HTTL3MBTL1
SCHEMBL437499 0.82 FFAR1 (0.58) FFAR1ALDH1A1SMN1; SMN2HTTMAPT
SCHEMBL437500 0.82 FFAR1 (0.58) FFAR1ALDH1A1SMN1; SMN2HTTMAPT
SCHEMBL22668454 0.81 FFAR1 (0.65) FFAR1ALDH1A1SMN1; SMN2HTTMAPT
SCHEMBL15239401 0.80 FFAR1 (0.76) FFAR1PPARGALDH1A1SMN1; SMN2HTT
SCHEMBL10267704 0.80 FFAR1 (0.76) FFAR1PPARGALDH1A1SMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2595952-B1 AGONISTS OF GPR40 CONNEXIOS LIFE SCIENCES PVT LTD (IN) 2020-11-18 EP disclosed
US-9278915-B2 Agonists of GPR40 CONNEXIOS LIFE SCIENCES PVT LTD (IN) 2016-03-08 US disclosed
US-20130237571-A1 AGONISTS OF GPR40 Conexios Life Sciences PVT. LTD. (IN) 2013-09-12 US disclosed
EP-2595952-A1 AGONISTS OF GPR40 Connexios Life Sciences Pvt. Ltd. (IN) 2013-05-29 EP disclosed
WO-2012011125-A1 AGONISTS OF GPR40 CONNEXIOS LIFE SCIENCES PVT. LTD. (IN) 2012-01-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130237571-A1 AGONISTS OF GPR40 GPR65, GPR55, GPR68 FFAR1 24/4885LTA4H 455/4885PPARG 51/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.